This Week in Diabetes & Endocrinology: AID Improves HbA1c, GLP-1 Fails on Stiffness, and New Insights in Obesity

This week's research highlights advances in diabetes technology and obesity management, while also revealing limitations of certain drug effects and exploring novel interventions. The most significant finding comes from a 13-week randomized controlled trial of 188 children and adults with type 1 diabetes and elevated HbA1c, which demonstrated that tubeless automated insulin delivery (AID) reduced HbA1c by 0.8% more than multiple daily injections. No severe hypoglycemia or diabetic ketoacidosis occurred in either group, suggesting AID may offer a safe short-term advantage for glycemic control, though longer-term data are needed to confirm durability and safety.

In contrast, a pharmacologic intervention showed limited vascular benefit. A proof-of-concept RCT in 90 people with type 2 diabetes and chronic kidney disease found that 24 weeks of treatment with the GLP-1 receptor agonist lixisenatide did not significantly improve aortic pulse wave velocity, a measure of arterial stiffness, compared to placebo. While the drug reduced HbA1c, it showed no significant changes in cardio-renal biomarkers, indicating it may not improve this specific vascular surrogate in this high-risk population. Obesity management research provided exploratory insights, with a post hoc analysis of the SURMOUNT-5 trial linking achievement of a waist-to-height ratio (WHtR) below 0.53 to higher odds of reaching low disease activity to remission states with tirzepatide or semaglutide. Separately, an analysis of 9,897 postmenopausal women suggested European Americans with a high BMI polygenic risk score regained nearly twice as much weight per year after initial loss, though this genetic interaction requires validation in more diverse populations.

Several studies explored adjunctive non-pharmacologic strategies. A 6-week RCT in 90 Bangladeshi adults with type 2 diabetes found a structured, physiotherapist-led exercise program improved capillary blood glucose and fitness compared to medication alone. In wound care, a pilot RCT of 40 patients with plantar diabetic foot ulcers found similar 12-week healing rates between a minimal offloading dressing (95%) and traditional felted foam (85%), with a numerically shorter median healing time for the new dressing that was not statistically significant. For pediatric metabolic health, an 8-week RCT in 40 overweight/obese children with PKU and NAFLD found a free walking program improved liver enzymes and BMI compared to a waitlist control.

Two pilot studies highlighted innovative intervention approaches. A qualitative sub-study of 100 low-income Pennsylvania Medicaid patients with hypertension or diabetes explored an unconditional cash transfer program, finding participants primarily used funds for basic needs and identified potential pathways to health improvement like reduced stress. A separate pilot RCT in 40 adults with type 1 diabetes demonstrated high feasibility and acceptability for a digital behavioral intervention (HypoPals) aimed at hypoglycemia, with 98% retention, though it reported no effectiveness outcomes. Finally, a Phase 2 trial proposal was noted, aiming to use advanced imaging and sequencing to study airway remodeling in obese asthma, though results are not yet available.

Clinically, this week's data reinforce the growing role of automated insulin delivery for type 1 diabetes management while suggesting that not all GLP-1 receptor agonist effects extend to vascular surrogates in advanced kidney disease. The exploratory obesity data on WHtR thresholds and genetic risk scores point to potential future tools for personalizing weight management, but they remain investigational. The positive, though preliminary, results for structured exercise, novel offloading dressings, and walking programs underscore the continued importance of lifestyle interventions across the spectrum of endocrine and metabolic conditions. The pilot studies on cash transfers and digital tools open intriguing avenues for addressing social determinants of health and behavioral management, though they require rigorous efficacy testing. Overall, the field continues to advance through a combination of technological innovation, drug development, and a renewed focus on practical, accessible adjunctive therapies.